Last checked at 23 Dec 2010 07:00
Proteome Sciences plc
Proteome Sciences Appoints Dr. Anthony Walker as Non-Executive Director
23 December, 2010 - Proteome Sciences plc (AIM:PRM), a leading provider of protein biomarker discovery, validation, and assay development services, is pleased to announce that Dr. Anthony Ian Walker has been appointed to the Board of the Company as a non-executive Director.
Dr. Walker (50) has considerable commercial and scientific expertise in the life sciences and biotechnology industries with 12 years as CEO and a director of Onyvax, a cancer vaccines company he co-founded in 1997, and currently as a partner at Alacrita LLP. In addition, Dr. Walker is a board member of Plastic Antibodies Ltd.
Previously, he spent ten years as a management consultant specialising in the pharmaceutical and biotechnology industries, initially at Arthur D. Little where he launched the UK Pharmaceutical Practice and subsequently at The Wilkerson Group.
At the AGM, it was announced that Professor Alf Lindberg was proposing to retire in January 2011 as a non-executive director, but he would continue to act on the Scientific Advisory Board.
The Board of Proteome Sciences would formally like to thank him for the considerable contribution and support that he has provided to the Company over a period in which the Company's outstanding biomarker research has been converted into product and commercial revenue. We wish him a most enjoyable retirement.
Further information on Dr Walker
In April 2009, Onyvax Ltd appointed administrators and sold intellectual property to Vaxonoco Inc. In September 2009 Onyvax Ltd came out of administration and commenced company voluntary arrangements which will remain in place until at least September 2012.
There is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules.
- Ends -
For further information please contact:
Proteome Sciences plc
www.proteomics.com Tel: +44 (0)1932 865065
Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com
James Malthouse, Finance Director james.malthouse@proteomics.com
Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com
Dr. Rainer Voegeli, Commercial Director rainer.voegeli@proteomics.com
Nominated Adviser
Singer Capital Markets Limited
Shaun Dobson/Claes Spång
Tel: +44 (0)20 3205 7500
Public Relations
IKON Associates Redleaf Communications Limited
Adrian Shaw Anna Dunkin/Lucy Salaman
Tel: +44 (0)1483 535102 Tel: +44 (0)20 7566 6700
Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com
Email: adrian@ikonassociates.com
About Proteome Sciences
Proteome Sciences is a global leader in applied proteomics and uses high sensitivity proprietary technologies for protein biomarker discovery, validation and assay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications. These biomarkers are available for outlicensing. The first blood test for lung cancer using Proteome Sciences' biomarkers was launched in the USA in 2009 and received Medicare reimbursement in 2010. Its PS Biomarker Services provides ISO 9001: 2008 accredited facilities in Frankfurt, Germany, using proprietary isobaric and isotopic Tandem Mass Tags® (TMT®) to discover protein biomarkers, and reference materials combined with isotope dilution mass spectrometry. Highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in validation studies. Assays for validated biomarkers can be transferred for immunoassay development. Proteome Sciences, based in Cobham, UK, has facilities in London and Frankfurt and delivers outsourced proteomics services and proprietary biomarkers to pharmaceutical, biotechnology and diagnostics companies. Visit http://www.proteomics.com.